Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 695-930-2 | CAS number: 13676-53-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
LD50 (experimental) >2000 mg/kg bw (LD50 cut-off = 5000 mg/kg bw), study conducted according to OECD 423, GLP
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2017-04-03 to 2017-07-24
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- adopted 17 December, 2001
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Version / remarks:
- 30 May 2008
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Version / remarks:
- December 2002
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 8-10 weeks
- Weight at study initiation: step 1, animals no. 1 – 3: 152 - 169 g; step 2, animals no. 4 – 6: 165 - 174 g; step 3, animals no. 7 – 9: 173 - 186 g
- Fasting period before study: food was withheld from the test animals for 16 to 19 h prior to test start
- Housing: The animals were kept in groups in IVC cages, type III H, polysulphone cages on Altromin saw fibre bedding
- Diet (e.g. ad libitum): ad libitum; Altromin 1324 maintenance diet for rats and mice
- Water (e.g. ad libitum): ad libitum; tap water, sulphur acidified to a pH value of approximately 2.8
- Acclimation period: at least five days under laboratory conditions
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): 55 ± 10
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12/12
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 0.3 g and 2.0 g
- Amount of vehicle (if gavage): 10 mL/kg
- Justification for choice of vehicle: vehicle was chosen due to its non-toxic characteristics
- Lot/batch no. (if required): MKBZ9899V
MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg
- Doses:
- 300 mg/kg bw in the first step and 2000 mg/kg bw in the second and third step
- No. of animals per sex per dose:
- 3 per step
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: weighing on day 1 (prior to start), 8 and 15, clinical examination was performed after dosing with special attention during the first 4 h post-dose period and once daily thereafter.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, necropsy incl. macroscopic findings - Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Remarks:
- experimental
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Sex:
- female
- Dose descriptor:
- LD50 cut-off
- Effect level:
- > 5 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- During step 1 (dose: 300 mg/kg bw) of the test no mortality was observed, during step 2 (dose 2000 mg/kg bw) one animal died spontaneously. During step 3 no compound-related mortality was reported.
- Clinical signs:
- other: The animals in step 1 (dose 300 mg/kg bw) exhibited the following clinical signs either until day 2 post exposure (animal 1 & 2) or 240 min post exposure (animal 3): Slightly reduced spontaneous activity, sunken flunks, slight piloerection, hunched postur
- Gross pathology:
- The necropsy of the spontaneously died animal revealed a dark discoloured duodenum, jejunum and ileum with Peyer’s patches. No specific pathological changes were recorded for surviving animals.
- Interpretation of results:
- Category 5 based on GHS criteria
- Conclusions:
- In the present study conducted according to OECD guideline 423 (adopted 17 December 2001), m-Xylylenebismaleimide was tested in three steps and two doses for acute oral toxicity. In step 1 300 mg/kg bw were adminstered and in steps 2 and 3 2000mg/kg bw were administered to three female rats each group and the animals were observed for 14 days. There were no premature deaths in step 1, thus step 2 was performed, one animal died in step 2 and all animals showed clinical signs during the first 5 to 7 days which were reversible. Body weight loss occurred in step 2 and 3 but all animals gained weight in a normal range at the end of the study.
Thus, according to Regulation (EC) No 1272/2008 (CLP) m-Xylylenebismaleimide is not classified with regard to acute oral toxicity; according to GHS (Globally Harmonized Classification System) m-Xylylenebismaleimide is classified into Category 5 and has obligatory labelling requirements for toxicity.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- The value was determined in a study conducted according to OECD guideline 423 and was GLP-compliant. Therefore, the results are of high quality.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In the present study conducted according to OECD guideline 423 (adopted 17 December 2001), m-Xylylenebismaleimide was tested in three steps and two doses for acute oral toxicity. In step 1, 300 mg/kg bw were adminstered and in steps 2 and 3, 2000mg/kg bw were administered to three female rats each group and the animals were observed for 14 days. There were no premature deaths in step 1, thus step 2 was performed, one animal died in step 2 and all animals showed clinical signs during the first 5 to 7 days which were reversible. Most prominent clinical signs were reduced spontaneous activity, sunken flunks, piloerection , half eyelid closure, prone position and between observation day 3 and 4 diarrhoea and weight loss. Body weight loss occurred in step 2 and 3 but all animals gained weight in a normal range at the end of the study. between observation day 7 and 15 there were no specific findings in step 2 and 3. The animal that died showed discoloured, dark duiodenum, jejunum, ileum - with Peyer´s patches- during necropsy. Necropsy was also performed with the remaining animals at day 15 but showed no specific findings.
Oral LD50 (rat, females) >2000 mg/kg bw (LD50 cut-off = 5000 mg/kg bw)
Justification for classification or non-classification
Based on the available, reliable and relevant data m-Xylylenebismaleimide is not classified with regard to acute oral toxicity according to Regulation (EC) No 1272/2008 (CLP); according to GHS (Globally Harmonized Classification System) m-Xylylenebismaleimide is classified into Category 5 and has obliatory labelling requirements for toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
